Identification

Name
Fludrocortisone
Accession Number
DB00687  (APRD00756, DB02478)
Type
Small Molecule
Groups
Approved
Description

A synthetic mineralocorticoid with anti-inflammatory activity. [PubChem]

Structure
Thumb
Synonyms
  • 9alpha-FLUOROCORTISOL
  • Fludrocortison
  • Fludrocortisona
  • Fludrocortisone
  • Fludrocortisonum
  • Fluohydrocortisone
External IDs
StC 1400
Product Ingredients
IngredientUNIICASInChI Key
Fludrocortisone AcetateV47IF0PVH4514-36-3SYWHXTATXSMDSB-GSLJADNHSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FlorinefTablet0.1 mgOralPaladin Labs Inc1995-12-31Not applicableCanada
Florinef Acetate 0.1mgTablet.1 mgOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1958-12-311997-08-14Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fludrocortisone AcetateTablet.1 mg/1OralCardinal Health2008-05-09Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralImpax Generics2002-03-18Not applicableUs00115 7033 01 nlmimage10 0f4a07f0
Fludrocortisone AcetateTablet.1 mg/1OralAv Kare, Inc.2002-03-18Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralAmerincan Health Packaging2008-05-09Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralTeva2003-02-14Not applicableUs00555 0997 02 nlmimage10 b107d88e
Fludrocortisone AcetateTablet.1 mg/1OralWest Ward Pharmaceutical2011-07-22Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralRemedy Repack2011-10-032016-11-22Us
Fludrocortisone AcetateTablet.1 mg/1OralPd Rx Pharmaceuticals, Inc.2003-02-14Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-03-30Not applicableUs
Fludrocortisone AcetateTablet.1 mg/1OralAv Pak2011-08-01Not applicableUs
International/Other Brands
Adixone (Genopharm) / Astonin (Merck) / Cortineff (Polfa Pabianice) / Florinef Acetaat (Bristol-Myers Squibb) / Florinefe (Bristol-Myers Squibb) / Fludrocortison (Bristol-Myers Squibb) / Lonikan (Merck)
Categories
UNII
U0476M545B
CAS number
127-31-1
Weight
Average: 380.4504
Monoisotopic: 380.199902243
Chemical Formula
C21H29FO5
InChI Key
AAXVEMMRQDVLJB-BULBTXNYSA-N
InChI
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
IUPAC Name
(1R,2S,10S,11S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES

Pharmacology

Indication

For partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome.

Structured Indications
Pharmacodynamics

Fludrocortisone is a synthetic adrenocortical steroid possessing very potent mineralocorticoid properties and high glucocorticoid activity. It is indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease and for the treatment of salt-losing adrenogenital syndrome. The physiologic action of fludrocortisone acetate is similar to that of hydrocortisone. However, the effects of fludrocortisone acetate, particularly on electrolyte balance, but also on carbohydrate metabolism, are considerably heightened and prolonged. Mineralocorticoids act on the distal tubules of the kidney to enhance the reabsorption of sodium ions from the tubular fluid into the plasma; they increase the urinary excretion of both potassium and hydrogen ions.

Mechanism of action

Fludrocortisone binds the mineralocorticoid receptor (aldosterone receptor). This binding (or activation of the mineralocorticoid receptor by fludrocortisone) in turn causes an increase in ion and water transport and thus raises extracellular fluid volume and blood pressure and lowers potassium levels.

TargetActionsOrganism
AMineralocorticoid receptor
agonist
Human
UGlucocorticoid receptor
agonist
Human
UAndrogen receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

High

Metabolism

Hepatic, some renal.

Route of elimination
Not Available
Half life

3.5 hours

Clearance
Not Available
Toxicity

Effects of overexposure include irritation, cardiac edema, increased blood volume, hypertension, cardiac arrhythmias, enlargement of the heart, headaches, and weakness of the extremities.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Fludrocortisone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Fludrocortisone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Fludrocortisone.Approved
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fludrocortisone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Fludrocortisone.Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fludrocortisone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Fludrocortisone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Fludrocortisone.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Fludrocortisone.Approved, Withdrawn
AldesleukinFludrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Fludrocortisone can be decreased when combined with Algeldrate.Experimental
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Fludrocortisone.Investigational
AlmagateThe bioavailability of Fludrocortisone can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Fludrocortisone can be decreased when combined with Almasilate.Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Fludrocortisone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Fludrocortisone.Approved
AloglutamolThe bioavailability of Fludrocortisone can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Fludrocortisone.Experimental
AluminiumThe bioavailability of Fludrocortisone can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Fludrocortisone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Fludrocortisone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fludrocortisone.Approved
AmiodaroneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BFludrocortisone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Fludrocortisone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Fludrocortisone.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Fludrocortisone.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Fludrocortisone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Fludrocortisone.Approved, Investigational
AprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Fludrocortisone can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fludrocortisone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fludrocortisone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Fludrocortisone.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Fludrocortisone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Fludrocortisone.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Fludrocortisone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Fludrocortisone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Fludrocortisone.Experimental
BendroflumethiazideFludrocortisone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Fludrocortisone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Fludrocortisone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fludrocortisone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Fludrocortisone.Experimental
Bismuth SubcitrateThe bioavailability of Fludrocortisone can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Fludrocortisone can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Fludrocortisone can be increased when it is combined with Boceprevir.Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Fludrocortisone.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Fludrocortisone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Fludrocortisone.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Fludrocortisone.Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Fludrocortisone.Experimental
BumetanideFludrocortisone may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fludrocortisone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Fludrocortisone can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Fludrocortisone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.Approved
Capromab pendetideFludrocortisone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Fludrocortisone.Experimental
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Fludrocortisone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Fludrocortisone.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Fludrocortisone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fludrocortisone.Approved, Investigational
CeritinibFludrocortisone may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Fludrocortisone.Approved, Vet Approved
ChlorothiazideFludrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Fludrocortisone can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Fludrocortisone.Approved
ChlorthalidoneFludrocortisone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Fludrocortisone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Fludrocortisone.Experimental
CinoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cinoxacin.Approved, Withdrawn
ClarithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Fludrocortisone.Approved
CobicistatThe serum concentration of Fludrocortisone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Fludrocortisone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Fludrocortisone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fludrocortisone.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Fludrocortisone.Investigational
CyclopenthiazideFludrocortisone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Fludrocortisone.Investigational
DaidzeinThe serum concentration of Fludrocortisone can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Fludrocortisone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Fludrocortisone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Fludrocortisone.Investigational
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Fludrocortisone.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Fludrocortisone.Approved, Vet Approved
DienestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Diethylstilbestrol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Fludrocortisone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fludrocortisone.Approved
DihydrotestosteroneFludrocortisone may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Fludrocortisone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Fludrocortisone.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Fludrocortisone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Fludrocortisone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Fludrocortisone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Fludrocortisone.Approved
EquolThe serum concentration of Fludrocortisone can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Fludrocortisone can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.Approved
Etacrynic acidFludrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Fludrocortisone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Fludrocortisone.Experimental
Ethinyl EstradiolThe serum concentration of Fludrocortisone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Fludrocortisone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Fludrocortisone.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Fludrocortisone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Fludrocortisone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Fludrocortisone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Fludrocortisone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Fludrocortisone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Fludrocortisone.Approved
FenthionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Fludrocortisone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Fludrocortisone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fludrocortisone.Experimental
FingolimodFludrocortisone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Fludrocortisone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Fludrocortisone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Fludrocortisone.Experimental
FluoxymesteroneFludrocortisone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Fludrocortisone.Approved, Investigational
FosaprepitantThe serum concentration of Fludrocortisone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Fosphenytoin.Approved
FurosemideFludrocortisone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
GalantamineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Fludrocortisone can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Fludrocortisone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Fludrocortisone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Fludrocortisone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Fludrocortisone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Fludrocortisone.Approved
GLPG-0492Fludrocortisone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Fludrocortisone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fludrocortisone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Grepafloxacin.Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Fludrocortisone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Fludrocortisone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Fludrocortisone.Experimental
HexestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Fludrocortisone.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fludrocortisone.Approved, Investigational
HydrochlorothiazideFludrocortisone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideFludrocortisone may increase the hypokalemic activities of Hydroflumethiazide.Approved
HydrotalciteThe bioavailability of Fludrocortisone can be decreased when combined with Hydrotalcite.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Fludrocortisone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Fludrocortisone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Fludrocortisone.Approved
IdelalisibThe serum concentration of Fludrocortisone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Fludrocortisone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Fludrocortisone.Approved
IndapamideFludrocortisone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Fludrocortisone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Fludrocortisone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Fludrocortisone.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Fludrocortisone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Fludrocortisone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Fludrocortisone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Fludrocortisone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Fludrocortisone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Fludrocortisone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Fludrocortisone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fludrocortisone.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fludrocortisone.Withdrawn
ItraconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Fludrocortisone.Experimental
KetoconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Fludrocortisone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fludrocortisone.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Fludrocortisone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Fludrocortisone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Fludrocortisone.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Fludrocortisone.Experimental
LopinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Fludrocortisone.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fludrocortisone.Approved
LumacaftorThe serum concentration of Fludrocortisone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Fludrocortisone.Approved, Investigational
MagaldrateThe bioavailability of Fludrocortisone can be decreased when combined with Magaldrate.Withdrawn
Magnesium HydroxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Fludrocortisone.Approved
Magnesium silicateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium silicate.Experimental
Magnesium TrisilicateThe bioavailability of Fludrocortisone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Fludrocortisone.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Fludrocortisone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Fludrocortisone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Fludrocortisone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fludrocortisone.Approved
MesteroloneFludrocortisone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Fludrocortisone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Fludrocortisone.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Fludrocortisone.Approved
MethallenestrilThe serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideFludrocortisone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneFludrocortisone may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Metoclopramide.Approved, Investigational
MetolazoneFludrocortisone may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Fludrocortisone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Fludrocortisone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Fludrocortisone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
MitotaneThe serum concentration of Fludrocortisone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fludrocortisone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Fludrocortisone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Fludrocortisone.Experimental
MoxestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fludrocortisone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Fludrocortisone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Fludrocortisone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Fludrocortisone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nalidixic Acid.Approved
NandroloneFludrocortisone may increase the fluid retaining activities of Nandrolone.Experimental
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Fludrocortisone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
NefazodoneThe serum concentration of Fludrocortisone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Fludrocortisone.Approved
NevirapineThe serum concentration of Fludrocortisone can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Nicorandil.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Fludrocortisone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Fludrocortisone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fludrocortisone.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Fludrocortisone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludrocortisone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Fludrocortisone.Vet Approved
OxandroloneFludrocortisone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Fludrocortisone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Oxolinic acid.Experimental
OxymetholoneFludrocortisone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fludrocortisone.Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Fludrocortisone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Fludrocortisone.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Fludrocortisone.Approved, Withdrawn
PhenobarbitalThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fludrocortisone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Fludrocortisone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fludrocortisone.Approved, Investigational
PhenytoinThe serum concentration of Fludrocortisone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fludrocortisone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Fludrocortisone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pipemidic acid.Experimental
PiretanideFludrocortisone may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Fludrocortisone.Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Fludrocortisone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Fludrocortisone.Experimental
Polyestradiol phosphateThe serum concentration of Fludrocortisone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideFludrocortisone may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Fludrocortisone.Experimental
PrimidoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Fludrocortisone.Experimental
PromestrieneThe serum concentration of Fludrocortisone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Fludrocortisone.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Fludrocortisone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Fludrocortisone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Fludrocortisone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Fludrocortisone can be increased when it is combined with Quinestrol.Approved
QuinethazoneFludrocortisone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fludrocortisone.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fludrocortisone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Fludrocortisone.Experimental, Investigational
RifabutinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Fludrocortisone can be decreased when it is combined with Rifapentine.Approved
RitonavirThe serum concentration of Fludrocortisone can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Fludrocortisone.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Fludrocortisone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Fludrocortisone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rosoxacin.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Fludrocortisone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fludrocortisone.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Fludrocortisone.Approved
SaquinavirThe serum concentration of Fludrocortisone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Fludrocortisone.Approved
SecoisolariciresinolThe serum concentration of Fludrocortisone can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Fludrocortisone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Fludrocortisone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Fludrocortisone.Investigational
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludrocortisone.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sitafloxacin.Experimental
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Fludrocortisone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sparfloxacin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Fludrocortisone.Investigational
St. John's WortThe serum concentration of Fludrocortisone can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololFludrocortisone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Fludrocortisone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Fludrocortisone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Fludrocortisone.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Fludrocortisone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Fludrocortisone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Fludrocortisone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Fludrocortisone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Fludrocortisone.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Fludrocortisone.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fludrocortisone.Withdrawn
TelithromycinThe serum concentration of Fludrocortisone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Fludrocortisone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Fludrocortisone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Fludrocortisone.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Fludrocortisone.Approved
TestosteroneFludrocortisone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Fludrocortisone.Approved
TiboloneThe serum concentration of Fludrocortisone can be increased when it is combined with Tibolone.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Fludrocortisone.Investigational
TofacitinibFludrocortisone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Fludrocortisone.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Fludrocortisone.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Fludrocortisone.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Fludrocortisone.Approved
TorasemideFludrocortisone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Fludrocortisone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Fludrocortisone.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Fludrocortisone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trichlorfon.Vet Approved
TrichlormethiazideFludrocortisone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Fludrocortisone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Fludrocortisone.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Fludrocortisone.Investigational, Withdrawn
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fludrocortisone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Fludrocortisone.Approved, Investigational
VoriconazoleThe serum concentration of Fludrocortisone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinFludrocortisone may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Fludrocortisone.Approved
ZeranolThe serum concentration of Fludrocortisone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Fludrocortisone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Fludrocortisone.Withdrawn
Food Interactions
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Take with food to reduce irritation.

References

Synthesis Reference

U.S. Patent 2,957,013

General References
Not Available
External Links
Human Metabolome Database
HMDB14825
KEGG Compound
C07004
PubChem Compound
31378
PubChem Substance
46508616
ChemSpider
29111
ChEBI
50885
ChEMBL
CHEMBL1201388
Therapeutic Targets Database
DAP001105
PharmGKB
PA164743961
IUPHAR
2873
Guide to Pharmacology
GtP Drug Page
HET
ZK5
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Fludrocortisone
ATC Codes
S02CA07 — Fludrocortisone and antiinfectivesS01CA06 — Fludrocortisone and antiinfectivesS03CA05 — Fludrocortisone and antiinfectivesH02AA02 — Fludrocortisone
AHFS Codes
  • 68:04.00 — Adrenals
PDB Entries
1gs4
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics1
1CompletedTreatmentDepressive State1
1CompletedTreatmentIdiopathic orthostatic hypotension / Multiple System Atrophy (MSA) / Parkinson's Disease (PD)1
1RecruitingNot AvailableHealthy Volunteers1
1, 2TerminatedBasic ScienceRenin Angiotensin1
2Active Not RecruitingTreatmentAutonomic Disturbances in Parkinson's Disease1
2RecruitingBasic ScienceHealthy Volunteers1
2RecruitingTreatmentPartial Mineralocorticoid Deficiency1
3CompletedTreatmentShock, Septic2
3WithdrawnTreatmentShock, Septic1
4CompletedTreatmentSyncope, Vasovagal, Neurally-Mediated1
4Unknown StatusDiagnosticHypertensive1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentIdiopathic orthostatic hypotension1
Not AvailableRecruitingNot AvailableAcidosis, Renal Tubular / Calcium Nephrolithiasis / Vacuolar Proton-Translocating ATPases1
Not AvailableRecruitingBasic ScienceMajor Depressive Disorder (MDD)1
Not AvailableRecruitingTreatmentHearing Loss, Sensorineural1
Not AvailableWithdrawnNot AvailableDiabetes, Diabetes Mellitus Type 11

Pharmacoeconomics

Manufacturers
  • King pharmaceuticals inc
  • Barr laboratories inc
  • Impax laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral0.1 mg
TabletOral.1 mg
TabletOral.1 mg/1
Prices
Unit descriptionCostUnit
Fludrocortisone acetate powder73.14USD g
Florinef acetate 0.1 mg tablet1.49USD tablet
Fludrocortisone Acetate 0.1 mg tablet0.81USD tablet
Fludrocortisone 0.1 mg tablet0.75USD tablet
Florinef 0.1 mg Tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility140 mg/L (at 25 °C)MERCK INDEX (1996)
logP1.67HANSCH,C ET AL. (1995)
logS-3.43ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.224 mg/mLALOGPS
logP1.35ALOGPS
logP1.32ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.55ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity96.93 m3·mol-1ChemAxon
Polarizability39.6 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9731
Caco-2 permeable+0.8415
P-glycoprotein substrateSubstrate0.7911
P-glycoprotein inhibitor INon-inhibitor0.8385
P-glycoprotein inhibitor IINon-inhibitor0.9351
Renal organic cation transporterNon-inhibitor0.7774
CYP450 2C9 substrateNon-substrate0.8799
CYP450 2D6 substrateNon-substrate0.909
CYP450 3A4 substrateSubstrate0.7138
CYP450 1A2 substrateNon-inhibitor0.9306
CYP450 2C9 inhibitorNon-inhibitor0.9023
CYP450 2D6 inhibitorNon-inhibitor0.9201
CYP450 2C19 inhibitorNon-inhibitor0.9285
CYP450 3A4 inhibitorNon-inhibitor0.8772
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.903
Ames testNon AMES toxic0.8895
CarcinogenicityNon-carcinogens0.9479
BiodegradationNot ready biodegradable0.9964
Rat acute toxicity2.1686 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9591
hERG inhibition (predictor II)Inhibitor0.5213
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-4-steroids / Halogenated steroids / Delta-4-steroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 24 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, 3-oxo Delta(4)-steroid, 20-oxo steroid, fluorinated steroid, mineralocorticoid, 21-hydroxy steroid, C21-steroid (CHEBI:50885) / C21 steroids (gluco/mineralocorticoids, progestogens) and derivatives (C07004) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030103)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates targ...
Gene Name
NR3C2
Uniprot ID
P08235
Uniprot Name
Mineralocorticoid receptor
Molecular Weight
107066.575 Da
References
  1. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P, Wiedemann K, Kellner M: The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci. 2003 Aug 22;73(14):1835-45. [PubMed:12888122]
  2. Oelkers W, Buchen S, Diederich S, Krain J, Muhme S, Schoneshofer M: Impaired renal 11 beta-oxidation of 9 alpha-fluorocortisol: an explanation for its mineralocorticoid potency. J Clin Endocrinol Metab. 1994 Apr;78(4):928-32. [PubMed:8157723]
  3. Young MJ, Funder JW: Mineralocorticoids, salt, hypertension: effects on the heart. Steroids. 1996 Apr;61(4):233-5. [PubMed:8733007]
  4. Kingsley-Kallesen M, Mukhopadhyay SS, Wyszomierski SL, Schanler S, Schutz G, Rosen JM: The mineralocorticoid receptor may compensate for the loss of the glucocorticoid receptor at specific stages of mammary gland development. Mol Endocrinol. 2002 Sep;16(9):2008-18. [PubMed:12198239]
  5. Buckley TM, Mullen BC, Schatzberg AF: The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology. 2007 Sep-Nov;32(8-10):859-64. Epub 2007 Jul 30. [PubMed:17666187]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Trune DR, Kempton JB: Low dose combination steroids control autoimmune mouse hearing loss. J Neuroimmunol. 2010 Dec 15;229(1-2):140-5. doi: 10.1016/j.jneuroim.2010.07.026. Epub 2010 Aug 30. [PubMed:20800906]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D: A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology. 2002 May;143(5):1889-900. [PubMed:11956172]
  2. Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P: Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem. 2002 Mar 28;45(7):1439-46. [PubMed:11906285]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 19:24